# STP-100

Source: https://onco.cc/drugs/stp-100/  
OnCo record `stp-100` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

STP-100 is an experimental antibody-drug conjugate from Stipple Bio, in preclinical development for cancer.

## Summary

STP-100 is an antibody-drug conjugate from Stipple Bio. An antibody-drug conjugate with a clinically validated linker-payload, built on tumour-specific binders, designed to avoid on-target, off-tumour toxicity. Target and indication are undisclosed. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Expected to enter clinical studies in early 2027 (company release, 6 April 2026). It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: STP-100
- Modality: Antibody-drug conjugate
- Mechanism: An antibody-drug conjugate with a clinically validated linker-payload, built on tumour-specific binders, designed to avoid on-target, off-tumour toxicity. Target and indication are undisclosed.

## Sources

- Stipple Bio: stipple.bio: https://stipple.bio/stipple-bio-emerges-from-stealth-with-oversubscribed-100-million-series-a-financing-to-advance-stp-100-into-early-clinical-studies-and-advance-a-precision-oncology-pipeline-that-leverages-its-pointil/
- Stipple Bio: stipple.bio: https://stipple.bio/pipeline/
- Stipple Bio: stipple.bio: https://stipple.bio/pipeline/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Stipple Bio](https://onco.cc/companies/stipple-bio/)

---
JSON: https://onco.cc/api/v1/entities/stp-100.json